ASRS 23: Pegcetacoplan Extension Study, and Comparison of Pegcetacoplan and Avacincaptad Pegol
New Retina Radio was at ASRS 2023 to cover the stories you may have missed.\xa0\n\xa0\nHow did patients fare in the GALE extension study, which assessed the safety and efficacy of pegcetacoplan (Syfovre, Apellis Pharmaceuticals) for geographic atrophy? Nathan C. Steinle, MD, shares the results of the first 6 months of GALE, in which patients who received treatment for 24 months in DERBY/OAKS continued with therapy\u2014and in which patients who had received sham treatment for 24 months were switched over to treatment.\xa0\n\xa0\nPaul Hahn, MD, PhD, joined us in our mobile studio in Seattle to share data from a matching-adjusted indirect comparison of pegcetacoplan and avacincaptad pegol (Izervay, Iveric Bio). What did he and his team find?\xa0\n\xa0\nThis is episode 2 of 2 covering the 2023 ASRS Annual Meeting. Go back in your feed to listen to episode 1.